- Home
- VATE vs PSNL Comparison
VATE vs PSNL Comparison
Compare VATE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | PSNL |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 729.1M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VATE | PSNL |
|---|---|---|
| Price | $15.28 | $11.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 55.7K | ★ 2.6M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $3.84 |
| 52 Week High | $16.71 | $11.50 |
Technical Indicators
Market Signals| Indicator | VATE | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 84.73 |
| Support Level | $4.48 | $6.68 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.23 | 0.77 |
| MACD | 0.19 | 0.53 |
| Stochastic Oscillator | 77.92 | 92.68 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.